Cargando…
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evid...
Autores principales: | Vantaggiato, Lorenza, Shaba, Enxhi, Cameli, Paolo, Bergantini, Laura, d’Alessandro, Miriana, Carleo, Alfonso, Montuori, Giusy, Bini, Luca, Bargagli, Elena, Landi, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861565/ https://www.ncbi.nlm.nih.gov/pubmed/36674438 http://dx.doi.org/10.3390/ijms24020925 |
Ejemplares similares
-
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy
por: Landi, Claudia, et al.
Publicado: (2020) -
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022) -
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020) -
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways
por: Shaba, Enxhi, et al.
Publicado: (2021) -
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)